Michael Pollante

Michael possesses expertise in CRISPR gene editing and stem cell biology. Prior to joining Stemson, Michael was a CIRM intern at the Sanford Consortium for Regenerative Medicine, where he investigated APOE-HDL transcytosis in iPSC-derived neurons as a model system to identify potential key factors of Alzheimer's Disease. He then transitioned to Thermo Fisher’s Cell Line Engineering group and spearheaded the CRISPR IVT Tools team and generated over 100 custom cell lines. Afterwards, he joined Fate Therapeutics, where he optimized Fate’s cellular reprogramming and engineering platform to advance Fate’s iPSC-derived iNK and iT cell therapy product candidates. Michael is currently working towards his bachelor’s degree in biology. In his free time, Michael enjoys playing soccer and driving along the Southern California coast.